The FDA Arthritis Advisory Committee voted 10 to 5 to recommend approval of a once-daily 2-mg dose of baricitinib for the treatment of adults with moderate to severe rheumatoid arthritis who have had an inadequate response to methotrexate.
Although the committee was near-unanimous on the positive efficacy of baricitinib (Olumiant, Incyte & Eli Lilly), its safety was much more controversial, with just a 9-member majority agreeing that the available data supported the safety of the 2-mg dose.
This activity is supported by educational funding provided by Amarin Pharma Inc., Amgen, and Quest Diagnostics.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.